Published in Drug Des Devel Ther on May 09, 2016
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 16.95
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Trends in heart failure incidence and survival in a community-based population. JAMA (2004) 8.90
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet (1997) 7.46
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Natriuretic peptides. N Engl J Med (1998) 6.04
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 4.38
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev (2005) 3.80
Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med (2008) 3.76
Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation (2003) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation (2014) 2.99
Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension (2010) 2.93
Epidemiology of heart failure. Circ Res (2013) 2.84
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation (2014) 2.75
Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J (2013) 2.74
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation (2006) 2.53
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther (1996) 2.32
Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J (1998) 2.30
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol (2014) 2.21
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
A new class of drugs for systolic heart failure: The PARADIGM-HF study. Cleve Clin J Med (2015) 2.01
Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens (2010) 2.00
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation (2002) 1.93
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med (2004) 1.79
Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail (2001) 1.78
Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J (2011) 1.67
The war against heart failure: the Lancet lecture. Lancet (2014) 1.63
Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol (2000) 1.50
Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens (2008) 1.44
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
Biology of natriuretic peptides and their receptors. Peptides (2005) 1.35
Neprilysin inhibition--a novel therapy for heart failure. N Engl J Med (2014) 1.26
The natriuretic peptides. Basic Res Cardiol (2004) 1.26
Blood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandins. Am J Physiol (1977) 1.25
Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem (1997) 1.24
Heart failure epidemiology: European perspective. Curr Cardiol Rev (2013) 1.14
To the Editor: The PARADIGM-HF trial. Cleve Clin J Med (2016) 1.08
Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J (2013) 1.08
Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. Basic Res Cardiol (2010) 1.05
Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol (2004) 1.03
Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides (1988) 1.03
On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat (2007) 1.02
Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension (2014) 1.02
Aging of the United States population: impact on heart failure. Curr Heart Fail Rep (2012) 1.00
Vasopeptidase inhibition: a double-edged sword? Hypertension (2003) 0.99
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol (2007) 0.96
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens (1992) 0.94
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci (2014) 0.94
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail (2004) 0.92
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem (1995) 0.90
Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension (1995) 0.90
Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (1998) 0.90
Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer (2004) 0.88
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens (1993) 0.88
CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail (2011) 0.87
UNITAID can address HCV/HIV co-infection. Lancet (2013) 0.87
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J (2015) 0.87
Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl (1999) 0.87
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail (2016) 0.85
Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol (1996) 0.84
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol (2011) 0.84
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother (2006) 0.84
The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharmacol Ther (2012) 0.84
Natriuretic peptides and cardio-renal disease. Int J Cardiol (2014) 0.84
Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens (1998) 0.83
Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant (2014) 0.83
The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol (1997) 0.83